Literature DB >> 16458111

Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells.

Jürgen Sonnemann1, Maite Hartwig, Andrea Plath, K Saravana Kumar, Cornelia Müller, James F Beck.   

Abstract

Histone deacetylase inhibitors (HDIs) are a promising new class of antineoplastic agents with the capacity to induce growth arrest and/or apoptosis of cancer cells. However, their precise mechanism of action is uncertain; particularly, the role of caspases in the apoptotic response to HDIs is controversial. Here, we show that the HDIs explored, suberoylanilide hydroxamic acid, sodium butyrate and trichostatin A, activated caspase-3 in A549 and PC-3 carcinoma cells. Additionally, the poly-caspase inhibitor z-VAD-fmk prevented HDI-induced apoptosis, as judged by determining mitochondrial membrane potential and by quantifying internucleosomal DNA fragmentation. Importantly, z-VAD-fmk also significantly inhibited HDI-elicited cell death, as assessed by measuring propidium iodide uptake. As an accessory finding, with the inhibition of caspases, a HDI-induced G2-M arrest became evident. Taken together, these results provide evidence that HDIs require activated caspases to induce apoptosis of carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16458111     DOI: 10.1016/j.canlet.2005.02.009

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  11 in total

1.  Butyrate increases the formation of anti-angiogenic vascular endothelial growth factor variants in human lung microvascular endothelial cells.

Authors:  J Ciura; P P Jagodziński
Journal:  Mol Biol Rep       Date:  2010-03-07       Impact factor: 2.316

2.  Valproic acid treatment response in vitro is determined by TP53 status in medulloblastoma.

Authors:  Bruna Mascaro-Cordeiro; Indhira Dias Oliveira; Francine Tesser-Gamba; Lorena Favaro Pavon; Nasjla Saba-Silva; Sergio Cavalheiro; Patrícia Dastoli; Silvia Regina Caminada Toledo
Journal:  Childs Nerv Syst       Date:  2018-05-22       Impact factor: 1.475

3.  Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action.

Authors:  Hiroaki Itamochi
Journal:  World J Biol Chem       Date:  2010-07-26

4.  Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells.

Authors:  Jürgen Sonnemann; Linn Dreyer; Maite Hartwig; Chithra D Palani; Le Thi Thu Hong; Ulrike Klier; Barbara Bröker; Uwe Völker; James F Beck
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-08       Impact factor: 4.553

5.  Genistein and beta-carotene enhance the growth-inhibitory effect of trichostatin A in A549 cells.

Authors:  Rong-Jen Shiau; Kai-Yong Chen; Yu-Der Wen; Cheng-Hung Chuang; Shu-Lan Yeh
Journal:  Eur J Nutr       Date:  2009-07-29       Impact factor: 5.614

Review 6.  Targeting caspases in cancer therapeutics.

Authors:  Patrick Hensley; Murli Mishra; Natasha Kyprianou
Journal:  Biol Chem       Date:  2013-07       Impact factor: 3.915

Review 7.  Malignant pleural mesothelioma.

Authors:  Anne S Tsao; Ignacio Wistuba; Jack A Roth; Hedy Lee Kindler
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

8.  Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.

Authors:  Jürgen Sonnemann; Jennifer Gänge; Sabine Pilz; Christine Stötzer; Ralf Ohlinger; Antje Belau; Gerd Lorenz; James F Beck
Journal:  BMC Cancer       Date:  2006-07-11       Impact factor: 4.430

Review 9.  Targeting histone deacetylases for the treatment of disease.

Authors:  M W Lawless; S Norris; K J O'Byrne; S G Gray
Journal:  J Cell Mol Med       Date:  2008-11-03       Impact factor: 5.310

10.  p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors.

Authors:  J Sonnemann; C Marx; S Becker; S Wittig; C D Palani; O H Krämer; J F Beck
Journal:  Br J Cancer       Date:  2013-11-26       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.